Analysts predict that Omeros Co. (NASDAQ:OMER) will report earnings of ($0.72) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Omeros’ earnings, with the highest EPS estimate coming in at ($0.70) and the lowest estimate coming in at ($0.73). Omeros reported earnings of ($0.07) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 928.6%. The firm is expected to announce its next earnings report on Thursday, November 8th.
According to Zacks, analysts expect that Omeros will report full-year earnings of ($2.67) per share for the current financial year, with EPS estimates ranging from ($2.71) to ($2.62). For the next financial year, analysts forecast that the company will report earnings of ($1.13) per share, with EPS estimates ranging from ($2.04) to ($0.22). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Omeros.
Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.04). The business had revenue of $1.70 million for the quarter, compared to the consensus estimate of $1.84 million. The firm’s quarterly revenue was down 90.1% compared to the same quarter last year. During the same period last year, the business posted ($0.33) EPS.
In related news, VP Marcia S. Kelbon sold 40,723 shares of the firm’s stock in a transaction on Friday, July 27th. The shares were sold at an average price of $21.56, for a total transaction of $877,987.88. Following the completion of the transaction, the vice president now owns 219,645 shares of the company’s stock, valued at $4,735,546.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Marcia S. Kelbon sold 7,529 shares of the firm’s stock in a transaction on Friday, August 31st. The stock was sold at an average price of $25.75, for a total transaction of $193,871.75. Following the transaction, the vice president now directly owns 227,645 shares of the company’s stock, valued at approximately $5,861,858.75. The disclosure for this sale can be found here. Company insiders own 12.10% of the company’s stock.
Several institutional investors have recently modified their holdings of the stock. BlueMountain Capital Management LLC purchased a new position in Omeros in the second quarter valued at $118,000. Quad Cities Investment Group LLC purchased a new position in Omeros in the second quarter valued at $161,000. Belpointe Asset Management LLC purchased a new position in Omeros in the second quarter valued at $204,000. Cubist Systematic Strategies LLC purchased a new position in Omeros in the second quarter valued at $274,000. Finally, Lesa Sroufe & Co purchased a new position in Omeros in the second quarter valued at $310,000. 48.11% of the stock is owned by hedge funds and other institutional investors.
OMER traded up $0.49 during trading on Monday, hitting $13.99. The stock had a trading volume of 607,922 shares, compared to its average volume of 1,037,468. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -17.71 and a beta of 3.49. Omeros has a twelve month low of $8.36 and a twelve month high of $27.00. The company has a quick ratio of 3.94, a current ratio of 3.95 and a debt-to-equity ratio of -2.31.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Recommended Story: What is a put option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.